Pharmacotherapy for Cushing disease: a recent Australian experience with osilodrostat

Internal Medicine JournalVolume 53, Issue 3 p. 451-452 Letter to the Editor Pharmacotherapy for Cushing disease: a recent Australian experience with osilodrostat Prishila Fookeerah, Corresponding Author Prishila Fookeerah [email protected] orcid.org/0000-0001-9314-9733 Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia School of Medicine, Western Sydney University, Sydney, New South Wales, AustraliaSearch for more papers by this authorMark McLean, Mark McLean Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia School of Medicine, Western Sydney University, Sydney, New South Wales, AustraliaSearch for more papers by this author Prishila Fookeerah, Corresponding Author Prishila Fookeerah [email protected] orcid.org/0000-0001-9314-9733 Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia School of Medicine, Western Sydney University, Sydney, New South Wales, AustraliaSearch for more papers by this authorMark McLean, Mark McLean Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia School of Medicine, Western Sydney University, Sydney, New South Wales, AustraliaSearch for more papers by this author First published: 27 March 2023 https://doi.org/10.1111/imj.16038Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol 2011; 75: 436–42. 2Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O. The incidence of endogenous Cushing's syndrome in the modern era. Clin Endocrinol 2019; 91: 263–70. 3Braun LT, Rubinstein G, Zopp S, Vogel F, Schmid-Tannwald C, Escudero MP et al. Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment. Endocrine 2020; 70: 218–31. 4Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M et al. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 2015; 172: R227–39. 5Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol 2021; 9: 847–75. 6Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al. Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 2022; 107: e2882–95. Volume53, Issue3March 2023Pages 451-452 ReferencesRelatedInformation